



PETER HARSANT RETIRES AFTER 14 YEARS AT NORGINE LTD

7 July 2005

Peter Harsant, latterly Managing Director of Norgine Limited, has retired after 14 years in the company.

Peter joined Norgine Ltd in 1991 as Managing Director from Novo Nordisk. During Peter's time as Managing Director he made a major contribution to building up the UK Company, increasing turnover by eight-fold. He was also largely responsible for expanding the capability of Norgine's UK manufacturing site located in Hengoed, making it one of the largest pharmaceutical facilities in Wales.

Peter was a member of the Norgine senior management team and active in a number of industry forums including Chair of the ABPI Wales Industry Group from its inception and the Pharma Industry representative on the All Wales Medicines Strategy Group.

"Norgine is extremely proud of all that Peter has achieved and we're delighted that later this year, he will work with us in a consultant role" said Peter Martin, Chief Operating Officer.

ENDS

Notes to editor

Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for almost 100 years and has a presence in all the major European markets. In 2004 Norgine's sales were €155 million, the 18th consecutive year of double-digit growth. The company employs 950 people, of which 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol® for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy, Fivasa® for the treatment of inflammatory bowel disease and Oramorph® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has nine products at various stages of clinical development including NRL994, a bowel preparation product. A European submission for NRL994 has already been filed and the company expects to submit an NDA in 2005.

Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Global Marketing and Business Development,
Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk